News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–36
Matches
80
Sources here
16
Companies here
5
Search results Stored financial headlines

Active search

80 matching headlines

Ticker or company: ZOEMain company stories
Clear

Zoetis (ZTS) Remains a Leader, So Why Was It Sold?

Polen Capital Management Llc released its "Polen Focus Growth Strategy" Q2 2026 investor letter. A copy of the letter can be downloaded here. Polen Focus Growth returned 6.33% (net of fees) in the second quarter of 2026, significantly underperforming the Russell 1000 Growth Index's …

ZTS main company Z1TS34 main company ZTS main company ZOTS main company ZOE main company
Sharemaestro market context Price below Trend Line 52 weeks -56.8% ZTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and …

ZTS main company Z1TS34 main company ZTS main company ZOTS main company ZOE main company
Sharemaestro market context Price below Trend Line 52 weeks -56.8% ZTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Zoetis (ZTS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Steve FrankChief Executive Officer - Kristin PeckChief Financial Officer - Wetteny Joseph TAKEAWAYS Revenue -- $2.5 billion, representing a flat result on …

ZTS main company Z1TS34 main company ZTS main company ZOTS main company ZOE main company
Sharemaestro market context Price below Trend Line 52 weeks -56.8% ZTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

AbCellera (ABCL) Rockets 44% as Hot Flash Treatment Brightens Growth Outlook

AbCellera Biologics Inc. (NASDAQ:ABCL) rallied for a third consecutive day on Monday to hit a new three-year high, after its drug candidate for hot flashes in menopausal women achieved strong clinical trial results, sparking long-term rosy growth prospects. In intra-day trading, the stock surged …

ZOE main company
Sharemaestro market context Price below Trend Line 52 weeks -51.4% ZOE stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Zoetis Stock: Is Wall Street Bullish or Bearish?

Zoetis sign at their Canadian By JHVEPhoto Parsippany, New Jersey-based Zoetis Inc. (ZTS) discovers, develops, manufactures, and commercializes medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry. Valued at $30.5 billion by market cap, …

ZTS main company ZOE main company
Sharemaestro market context Price below Trend Line 52 weeks -52.3% ZTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Zoetis (ZTS) Looked Like a Winner. What Went Wrong?

Brown Advisory, an investment management company, released its "Brown Advisory Global Leaders Strategy" for the second quarter of 2026 investor letter. A copy of the letter can be downloaded here. Brown Advisory's Global Leaders Strategy delivered a net return of 4.6% in the second …

ZTS main company Z1TS34 main company ZTS main company ZOTS main company ZOE main company
Sharemaestro market context Price below Trend Line 52 weeks -56.8% ZTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Zoetis Q2 Earnings Call Highlights

Key Points Interested in Zoetis Inc.? Here are five stocks we like better. Zoetis reported mixed second-quarter results: Revenue was $2.5 billion, flat reported and down 1% organically, while adjusted EPS rose 4% to $1.87 due partly to share repurchases. Weak U.S. companion-animal demand …

ZTS main company Z1TS34 main company ZTS main company ZOTS main company ZOE main company
Sharemaestro market context Price below Trend Line 52 weeks -56.8% ZTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Zoetis (ZTS) Stock Sinks After Guidance Cut Deepens Profit Concerns

Zoetis (ZTS) stock fell almost 6% after the company cut its full-year guidance, now expecting adjusted diluted earnings per share between US$6.15 and US$6.25 and a mid to high single-digit decline in organic adjusted net income. This guidance cut was largely driven by a …

ZTS main company
Sharemaestro market context Price below Trend Line 52 weeks -52.3% ZTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Zoetis Earnings: Full Force of Heightened Competition on Display; Cutting Our Fair Value Estimate

Zoetis reported flat top-line growth and a 5% decline in earnings year over year for its second quarter, primarily due to an 11% drop in US companion animal revenue. Consequently, the company significantly reduced its revenue and earnings per share guidance. Morningstar has lowered …

ZTS main company
Sharemaestro market context Price below Trend Line 52 weeks -52.3% ZTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Zoetis (ZTS) Following Earnings And Guidance Cut With A Valuation Question

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Zoetis earnings, guidance cut and new CFO/COO appointment grab investor attention Zoetis (ZTS) is …

ZTS main company ZOE main company
Sharemaestro market context Price below Trend Line 52 weeks -52.3% ZTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure

Zoetis Inc. ZTS used its second-quarter 2026 earnings call to reset expectations for 2026 as weaker veterinary clinic traffic, pet-owner price sensitivity and heavier competition pressured major Companion Animal franchises. CEO Kristin Peck said management is not assuming the market becomes easier soon. The …

ZTS main company ZOE main company
Sharemaestro market context Price below Trend Line 52 weeks -52.3% ZTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

As Competition Crowds Zoetis, We Lower Our Fair Value Estimate

Morningstar has lowered its fair value estimate for Zoetis (ZTS) due to increased competition in the animal health industry. Despite this, Zoetis is still considered the leader in the global animal health industry, known for its innovation across a wide range of products and …

ZTS main company
Sharemaestro market context Price below Trend Line 52 weeks -52.3% ZTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Zoetis Inc. Q2 2026 Earnings Call Summary

Zoetis Inc. Q2 2026 Earnings Call Summary - Moby Strategic Performance Drivers and Market Dynamics Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

ZTS main company ZOE main company
Sharemaestro market context Price below Trend Line 52 weeks -52.3% ZTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Here's What Key Metrics Tell Us About Zoetis (ZTS) Q2 Earnings

Zoetis (ZTS) reported $2.47 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 0.3%. EPS of $1.87 for the same period compares to $1.76 a year ago. The reported revenue represents a surprise of -0.95% over the Zacks Consensus …

ZTS main company ZOE main company
Sharemaestro market context Price below Trend Line 52 weeks -52.3% ZTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Zoetis (NYSE:ZTS) Misses Q2 CY2026 Sales Expectations

Zoetis (NYSE:ZTS) Misses Q2 CY2026 Sales Expectations Animal health company Zoetis (NYSE:ZTS) fell short of the market's revenue expectations in Q2 CY2026, with sales flat year on year at $2.47 billion. The company's full-year revenue guidance of $9.22 billion at the midpoint came in …

ZTS main company ZOE main company
Sharemaestro market context Price below Trend Line 52 weeks -52.3% ZTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Zoetis Sees Softer Pet Health Demand, But Adapting Commercial Strategy to Navigate Headwinds

Zoetis Inc. (NYSE: ZTS) reported Q2 adjusted earnings of $1.87 per share, beating consensus, but sales of $2.468 billion missed estimates, showing flat year-over-year revenue. The company noted softer demand in the companion animal market due to lower clinic visits and pet owner price …

ZTS main company
Sharemaestro market context Price below Trend Line 52 weeks -52.3% ZTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Zoetis (ZTS) Surpasses Q2 Earnings Estimates

Zoetis (ZTS) came out with quarterly earnings of $1.87 per share, beating the Zacks Consensus Estimate of $1.84 per share. This compares to earnings of $1.76 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

ZTS main company ZOE main company
Sharemaestro market context Price below Trend Line 52 weeks -52.3% ZTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Zoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating Officer

Saccaro's Appointment is Effective August 17, 2026; Wetteny Joseph to Serve as a Special Advisor to the CEO on Financial Matters Until Early 2027 PARSIPPANY, N.J., August 06, 2026--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced the appointment of James (Jay) Saccaro as Executive Vice …

ZTS main company ZOE main company
Sharemaestro market context Price below Trend Line 52 weeks -52.3% ZTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Zoetis Announces Second Quarter 2026 Results

Revenue Flat at $2.5 Billion and Net Income of $691 Million, or $1.65 per Diluted Share, Decreasing 5% and Increasing 1%, Respectively, on a Reported Basis Adjusted Net Income of $781 Million, or Adjusted Diluted EPS of $1.87 Revenue and Adjusted Net Income Declined …

ZTS main company ZOE main company
Sharemaestro market context Price below Trend Line 52 weeks -52.3% ZTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

How Burry’s Bet and OA Pipeline Push Will Impact Zoetis (ZTS) Investors

Recently, investor Michael Burry increased his position in Zoetis, as the company works through competitive pressures and safety concerns around some companion animal osteoarthritis products while advancing 12 pipeline candidates targeting unmet medical needs. Zoetis has also rolled out new osteoarthritis therapies in Canada …

Z1TS34 main company ZTS main company ZOE main company
Sharemaestro market context Price below Trend Line 52 weeks -54.2% Z1TS34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026

The Bull Case for Zoetis Stock as Michael Burry Doubles Down

Zoetis sign at their Canadian By JHVEPhoto Animal healthcare company Zoetis (ZTS) faces headwinds from companion animal product sales due to a competitive landscape, primarily from its key dermatology franchise and Simparica Trio. Moreover, Zoetis' Convenia and Cerenia brands face heightened competition from generic …

ZTS main company ZOE main company
Sharemaestro market context Price below Trend Line 52 weeks -52.3% ZTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context